Search clinical trials for: high dose chemo then auto hematopoietic cell transplant

Total 46 results

Stanford University

Completed

High Dose Chemotherapy Followed By PBSC Rescue for HD

Hodgkin Disease

United States
Stanford University

Completed

Autologous Stem Cell Rescue for Primary Amyloidosis

Amyloidosis | Blood and Marrow Transplant (BMT)

United States
Stanford University
National Institutes of Health (NIH)

Completed

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

United States
Stanford University

Unknown

High Dose Chemotherapy and Autologous Transplant for Breast Cancer

Graft vs Host Disease

United States
Stanford University

Completed

CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

Breast Cancer

United States
Stanford University

Completed

Transplantation for Patients With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic

United States
Stanford University

Completed

Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

Leukemia | Leukemia, Myelocytic, Acute | Blood and Marrow Transplant (BMT)

United States
Stanford University

Completed

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

Multiple Myeloma

United States
Stanford University

Completed

Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease

Graft vs Host Disease | Blood and Marrow Transplant (BMT)

United States
David Rizzieri, MD

Completed

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Sickle Cell Anemia | Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Severe Aplastic Anemia

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Otsuka America Pharmaceutical

Completed

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

Non-Hodgkin's Lymphoma | CNS Lymphoma

United States
University of Arkansas

Completed

UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma

Multiple Myeloma

United States
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

COVID-19

China
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA; ZHONGYIANKE... and other collaborators

Recruiting

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

COVID-19

China
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
M.D. Anderson Cancer Center

Completed

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Metastatic Breast Carcinoma

United States
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE...

Recruiting

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

COVID-19

China
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

Multiple Myeloma

United States, Canada
Acrotech Biopharma Inc.
Clinipace Worldwide; Beckloff Associates, Inc.; Kansas City Bioanalytical Laboratories

Completed

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Myeloma

United States
Wen-Kai Weng

Completed

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Multiple Myeloma | Blood Cancer

United States
Memorial Sloan Kettering Cancer Center
Otsuka America Pharmaceutical; Ludwig Institute for Cancer Research

Completed

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Multiple Myeloma

United States
Washington University School of Medicine

Terminated

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy

Testicular Germ Cell Tumor | Brain and Central Nervous System Tumors | Extragonadal Germ Cell Tumor

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Recruiting

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Hematologic Malignancies

United States
Kite, A Gilead Company

Active, not recruiting

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

United States, Spain, United Kingdom, Canada, Netherlands, Germany, France, Sweden, Israel, Switzerland, Belgium, Australia, Austria, Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States
Masonic Cancer Center, University of Minnesota

Completed

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Ovarian Cancer | Teratoma | Childhood Germ Cell Tumor

United States
National Cancer Institute (NCI)

Completed

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Multiple Myeloma | Hodgkin's Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Non-Hodgkin's Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States, Germany, Denmark
National Cancer Institute (NCI)

Recruiting

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; University of Washington; H. Lee...

Active, not recruiting

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

T Cell Non-Hodgkin Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Michael Pulsipher, MD

Active, not recruiting

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Severe Aplastic Anemia

United States
Boston Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Recruiting

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (TransIT)

Severe Aplastic Anemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
University of Nebraska
National Cancer Institute (NCI)

Completed

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Hepatosplenic T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Stage II Angioimmunoblastic T-cell Lymphoma | Stage II Enteropathy-Associated T-Cell Lymphoma | Stage III Angioimmunoblastic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...

United States
University of Leeds
Merck Sharp & Dohme LLC; Celgene; Amgen

Unknown

Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (Myeloma XI)

Multiple Myeloma

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia, New Zealand

Search clinical trials for: high dose chemo then auto hematopoietic cell transplant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations